The MyRealWorld Myasthenia Gravis Registry
Running from 2019 to 2024, the registry collected extensive patient‑reported data across symptoms, treatment patterns, healthcare utilisation, and quality of life, providing one of the largest international real‑world MG datasets to date.
For those with MG
I am a clinician working in MG
I am a researcher working in MG
Partnership with Patient Advocacy Groups Across 10 Countries
- Selecting variables that truly reflect the lived burden of MG
- Ensuring cultural and clinical relevance across diverse health systems
- Supporting patient engagement and retention
- Representing the patient voice in registry governance
This multi‑country PAG partnership enabled a deeply patient‑centered design and ensured that the registry reflected the daily realities of MG across North America, Europe, and Asia.
Scientific Advisory Board
The registry was governed by an independent, international Scientific Advisory Board (SAB) comprising leading MG clinicians, patient advocacy representation, and sponsor representatives. The SAB provided oversight of scientific rigor, participant interests, data access requests, and publication strategy.
About The VRMG Registry
Data Variables
The MyRealWorld™ MG registry captured a rich, granular dataset combining custom survey variables, highfrequency longitudinal trackers, and a wide suite of validated patient-reported outcome (PRO) instruments.
Across ten countries, the registry collected detailed information on demographics, MG subtype, diagnostic pathway, antibody status, MGFA class, thymus involvement, comorbidities, lifetime and recent treatment history, rescue therapy use, sideeffects, treatment satisfaction, healthcare utilisation, exacerbations, work and productivity impact, living situation, and caregiver burden. Monthly trackers added further depth by capturing treatment changes, symptom burden, healthcare visits, and time costs.
This was complemented by a uniquely comprehensive PRO set, including EQ-5D-5L (with MG-relevant bolt-ons), MG-ADL, MG-QoL15r, HADS, HUI-3, PROMIS measures, and FACIT Fatigue. This enabled a multi-dimensional, longitudinal view of real-world MG burden and quality of life with exceptional granularity.
A Unique MG dataset
Built with, not just for, the MG community
The registry was co developed with PAGs and clinicians in each country, ensuring relevance to real world clinical practice and patient needs.
One of the largest international MG Patient-Reported Outcome datasets
With ~2,100 participants across 10 countries, it captured wide variation in disease experiences, healthcare systems, and treatment pathways.
Rich, granular data on real-world MG
The dataset included:
• Demographics and diagnostic journey
• MGFA class, antibody status, thymus involvement
• Detailed treatment pathways (lifetime + 12 month windows)
• Rescue therapies
• Side effects and treatment satisfaction
• Exacerbations and healthcare utilisation
• Living situation, caregiver burden, and work/study impact
High frequency symptom and treatment tracking
Monthly tracker surveys captured changes in treatment, symptoms, work productivity, and healthcare visits — enabling longitudinal insight into how MG evolves and impacts daily life.
A global perspective on MG
By spanning 10 countries, MyRealWorld™ MG produced internationally comparable insights reflecting real differences in care, treatment access, and disease burden.
COVID-19 add-on module during 2020-2021
A bespoke PRO instrument captured the pandemic’s specific impact on people with MG, later removed when no longer needed.
Flexible data capture
Modular setup supports different study designs, sites, and country-level requirements while keeping a consistent participant experience.
Our Publications
How should the PFDD guidance for medicines development inform the conduct of RW research?
What PFDD guidance can teach us about better real-world research My career has been spent spanning the medicines development lifecycle, from first-in-human dosing to commercialization. The view from those different vantage points has left me convinced of one thing: if...
New Collaboration Helps Pharmaceutical Companies Generate Greater Value from Global Managed Access Programs
Partnership combines enterprise technology with real-world evidence expertise to maximise the strategic value of Managed Access Programs.Maprium, the company behind the Managed Access Operating System, today announced a strategic collaboration with Vitaccess, a...
Should individualised benefit-harm assessment be a core part of real-world research?
Benefit-risk (of harm) assessment is the cornerstone of decision making in medical care [1]. Aggregated clinical trial data plays a critical role in both bringing treatments to market (by informing licensing and reimbursement) and in informing treatment decisions made...
Patient-centric research: lessons learned from more than 20 years in Health Psychology
My journey into patient centricity Nearly a quarter of a century ago I qualified as a Practitioner Health Psychologist. At first, I was not quite sure what direction that would take me in, but then I found something I was passionate about - “patient centricity”....
Get Involved
Submit your enquiry below and our team will follow up to discuss how our Myasthenia Gravis registry can support your research goals. Academic researchers can also request information on the MGFA RFP, including a $10,000 award to support studies leveraging this dataset.